Live News EQUITY FLASH L impact Oct 12, 2026, 05:49 PM UTC BMO Capital Cuts Neurocrine Price Target to $150 From $164 BMO Capital maintained its Market Perform rating on Neurocrine. NBIX SquawkNews Desk